Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova (TKNO)
NASDAQ:TKNO
TKNO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.45 - $10.37
Previous CloseN/A
Volume51.57K
Average Volume (3M)347.34K
Market Cap
$232.47M
Enterprise Value$280.33M
Total Cash (Recent Filing)$3.38M
Total Debt (Recent Filing)$16.36M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 05, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding53,440,810
10 Day Avg. Volume280,874
30 Day Avg. Volume347,338
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue7.33
Enterprise Value/Gross Profit34.91
Enterprise Value/Ebitda-15.34
Forecast
1Y Price Target
$10.00Price Target Upside130.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ4 revenues of $9.3M beat the Street's $8.8M, showing stronger than expected performance.
ProfitabilityTeknova's path to profitability should boost investor confidence given the high level of visibility.
Revenue GrowthNew customer additions in both lab essentials and clinical solutions drove the strength.
Bears Say
Macroeconomic ImpactCautiousness from customers related to the funding environment and other macro uncertainties are important considerations that management confirmed are baked into the low end of the guide.
Order DelaysManagement noted that some customers have delayed orders and reduced budgets due to macro uncertainty.
Revenue Guidance2025 revenue guidance of $39-42M is below consensus estimates, leading to modest expected top line growth.
Alpha Teknova News
TKNO FAQ
What was Alpha Teknova’s price range in the past 12 months?
Alpha Teknova lowest stock price was $3.45 and its highest was $10.37 in the past 12 months.
What is Alpha Teknova’s market cap?
Alpha Teknova’s market cap is $232.47M.
When is Alpha Teknova’s upcoming earnings report date?
Alpha Teknova’s upcoming earnings report date is Nov 05, 2025 which is in 88 days.
How were Alpha Teknova’s earnings last quarter?
Alpha Teknova released its earnings results on Aug 07, 2025. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.03.
Is Alpha Teknova overvalued?
According to Wall Street analysts Alpha Teknova’s price is currently Undervalued.
Does Alpha Teknova pay dividends?
Alpha Teknova does not currently pay dividends.
What is Alpha Teknova’s EPS estimate?
Alpha Teknova’s EPS estimate is -0.1.
How many shares outstanding does Alpha Teknova have?
Alpha Teknova has 53,440,810 shares outstanding.
What happened to Alpha Teknova’s price movement after its last earnings report?
Alpha Teknova reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -2.535%.
Which hedge fund is a major shareholder of Alpha Teknova?
Currently, no hedge funds are holding shares in TKNO
Alpha Teknova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (130.41% Upside)
$10.00 (130.41% Upside)
Hedge Fund Trend
Increased
By 275.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.51%
12-Months-Change
Fundamentals
Return on Equity
-27.74%
Trailing 12-Months
Asset Growth
-5.65%
Trailing 12-Months
Company Description
Alpha Teknova
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
TKNO Company Deck
TKNO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with both positive and negative elements. While the company showed growth in overall revenue and improved gross margins, specific segments such as custom products and clinical solutions faced challenges. Additionally, uncertainties in the biotech funding environment could impact future performance. However, strategic collaborations and a reduction in net losses were positive indicators.View all TKNO earnings summariesTKNO Stock 12 Month Forecast
Average Price Target
$10.00
▲(130.41% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
SIGA Technologies
―
Aquestive Therapeutics
―
Ownership Overview
1.19% Insiders
1.60% Mutual Funds
0.02% Other Institutional Investors
94.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---